Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alogliptin
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alogliptin is an oral antidiabetic drug used to treat type 2 diabetes mellitus. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. Alogliptin works by selectively inhibiting the DPP-4 enzyme, which increases levels of incretin hormones such as GLP-1 and GIP. This leads to increased insulin secretion from pancreatic beta cells and decreased glucagon secretion from alpha cells in a glucose-dependent manner, thereby lowering blood glucose levels. Alogliptin is weight-neutral and has a low risk of hypoglycemia when used alone. It was developed by Takeda and is available as monotherapy (Nesina/Vipidia) or in combination with other agents for type 2 diabetes[1][2][3][4][5][7].
- Brand names
- NesinaVipidia
- Other names
- alogliptin benzoate
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on alogliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alogliptin.